PURI-HF (Air Purifiers on Heart Failure) forsøget
Effektivitet af indendørs luftrensere på hjertesvigt
Indoor air pollution and fine mode particulate matter with an aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and mortality, particularly due to cardiovascular disease. This project aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India. The findings from the project will add to existing knowledge of innovative and scalable strategies to improve environmental and cardiovascular health worldwide.
The overall objective of this study is to demonstrate the efficacy, feasibility, and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jessica Gjonaj
- Telefonnummer: 646-501-3663
- E-mail: Jessica.gjonaj@nyulangone.org
Undersøgelse Kontakt Backup
- Navn: Rajesh Vedanthan, MD, MPH
- Telefonnummer: 646-501-3890
- E-mail: Rajesh.vedanthan@nyulangone.org
Studiesteder
-
-
Kerala
-
Thiruvananthapuram, Kerala, Indien
- Rekruttering
- Centre for Chronic Disease Control (CCDC)
-
-
Punjab
-
Delhi, Punjab, Indien
- Rekruttering
- All India Institute of Medical Sciences (AIIMS)
-
Ludhiana, Punjab, Indien
- Rekruttering
- Public Health Foundation of India (PHFI)
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults ≥ 18 years of age diagnosed with HF with a reduced ejection fraction of ≤ 40% within the last six months in NYHA class II-IV.
Exclusion Criteria:
- listed for a cardiac transplant
- history of CRT device implantation in last 3 months
- on oxygen therapy
- with severe pulmonary disease
- participants unable to ambulate
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HEPA Air Purifier
Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period. |
The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold. |
|
Placebo komparator: EGAPA Air Purifier
Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period. |
Participants in the placebo arm will receive an air purifier with only the EGAPA filter. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Distance Walked
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
The distance in meters will be recorded during a 6-minute walk test (MWT) |
Baseline, 4 months, 8 months, 12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in Systolic Blood Pressure (SBP)
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
Baseline, 4 months, 8 months, 12 months
|
|
Change in Diastolic Blood Pressure (DBP)
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
Baseline, 4 months, 8 months, 12 months
|
|
Change in Heart Rate
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
Baseline, 4 months, 8 months, 12 months
|
|
Change in pro B-type natriuretic peptide (Pro-BNP) Levels
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
Baseline, 4 months, 8 months, 12 months
|
|
Change in Number of Hospitalizations
Tidsramme: Baseline, 4 months, 8 months, 12 months
|
Baseline, 4 months, 8 months, 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Rajesh Vedanthan, MD, MPH, NYU Langone Health
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 21-00954
- R01ES033222 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD-delingstidsramme
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD-delingsadgangskriterier
The investigator who proposed to use the data will have access upon reasonable request. Requests should be directed to rajesh.vedanthan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .